Literature DB >> 25551245

Attitudinal barriers to prescribing LAI antipsychotics in the outpatient setting: communicating with patients, families, and caregivers.

John M Kane1.   

Abstract

Patients with schizophrenia who are nonadherent to medication are at risk for repeated relapse and rehospitalization from this chronic and lifelong mental illness. Effective, oral medications can be difficult for patients to maintain on a daily basis, and long-acting injectable (LAI) antipsychotics can help to alleviate this challenge. However, some physicians' attitudinal barriers that need to be overcome include the belief that patients do not have adherence problems, concerns about LAI antipsychotic efficacy over traditional oral agents, the perception that the time and cost to administer this formulation outweighs its benefit, and the perception that injectable medications undermine patients' autonomy. A better understanding of LAIs and their potential benefits may help physicians to implement a long-term treatment plan that provides the best outcome for patients. © Copyright 2014 Physicians Postgraduate Press, Inc.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25551245     DOI: 10.4088/JCP.13024tx2c

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  6 in total

1.  Factors Associated with Adherence to the HEDIS Quality Measure in Medicaid Patients with Schizophrenia.

Authors:  Marie-Hélène Lafeuille; Christian Frois; Michel Cloutier; Mei Sheng Duh; Patrick Lefebvre; Jacqueline Pesa; Zoe Clancy; John Fastenau; Mike Durkin
Journal:  Am Health Drug Benefits       Date:  2016-10

Review 2.  Barriers to the Use of Long-Acting Injectable Antipsychotics in the Management of Schizophrenia.

Authors:  Eduard Parellada; Miquel Bioque
Journal:  CNS Drugs       Date:  2016-08       Impact factor: 5.749

3.  Enhancing adherence, subjective well-being and quality of life in patients with schizophrenia: which role for long-acting risperidone?

Authors:  Cinzia Niolu; Emanuela Bianciardi; Giorgio Di Lorenzo; Claudia Marchetta; Ylenia Barone; Nicoletta Sterbini; Michele Ribolsi; Giorgio Reggiardo; Alberto Siracusano
Journal:  Ther Adv Psychopharmacol       Date:  2015-10

Review 4.  Long-Acting Injectable Antipsychotics in Schizophrenia: Literature Review and Practical Perspective, with a Focus on Aripiprazole Once-Monthly.

Authors:  Enrico Biagi; Enrico Capuzzi; Fabrizia Colmegna; Alessandra Mascarini; Giulia Brambilla; Alessandra Ornaghi; Jacopo Santambrogio; Massimo Clerici
Journal:  Adv Ther       Date:  2017-04-05       Impact factor: 3.845

5.  Illness Perceptions in Patients of Schizophrenia: A Preliminary Investigation from Lahore, Pakistan.

Authors:  Sadia Hussain; Nazish Imran; Usman Amin Hotiana; Nauman Mazhar; Aftab Asif
Journal:  Pak J Med Sci       Date:  2017 Jul-Aug       Impact factor: 1.088

6.  Evidence-Based Expert Consensus Regarding Long-Acting Injectable Antipsychotics for Schizophrenia from the Taiwanese Society of Biological Psychiatry and Neuropsychopharmacology (TSBPN).

Authors:  Kai-Chun Yang; Yin-To Liao; Yen-Kuang Yang; Shih-Ku Lin; Chih-Sung Liang; Ya-Mei Bai
Journal:  CNS Drugs       Date:  2021-07-27       Impact factor: 5.749

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.